drugset

drugset / Trial / NCT00193232

Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer

NCT00193232 ↗

Phase 2 Completed 50 enrolled SCRI Development Innovations, LLC Aventis Pharmaceuticals · collab Millennium Pharmaceuticals, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Evaluation of the effectiveness of weekly docetaxel/bortezomib as first-line chemotherapy for patients with advanced hormone-refractory prostate cancer.

Timeline

Start: 2004-05
Primary completion: 2005-10
Completion: 2007-02

Publications

Results Hainsworth JD, Meluch AA, Spigel DR, Barton J Jr, Simons L, Meng C, Gould B, Greco FA. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial. Clin Genitourin Cancer. 2007 Mar;5(4):278-83. doi: 10.3816/CGC.2007.n.004.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	1.6 mg/m2	—
Subject	Docetaxel	Small molecule	30 mg/m2	—

Indications